Global CDMO giant Catalent announced changes to its operating structure and executive leadership team that went into effect July 1.
This new organizational structure consolidates the company's four reporting segments to two — one focused on biologics and the other on pharmaceuticals and consumer health.
The shift, according to Catalent's new CEO Alessandro Maselli, reflect "evolving customer and industry trends and position the company to deliver its next level of growth and achievement."
The new Pharma and Consumer Health segment consolidates the company’s Softgel & Oral Technologies segment, Oral & Specialty Delivery, and Clinical Supply Services segments. The segment will encompass the offerings of the three prior segments, including the company’s global pharma manufacturing platforms.
Catalent’s other reporting segment, Biologics, continues without any change.
The reorg has triggered some key leadership changes:
- As announced back in Jan., Maselli is serving as president and CEO, effective July 1, replacing John Chiminski. Chiminski has assumed the position of executive chair of the Board.
- Dr. Aris Gennadios, who previously lead the Softgel & Oral Technologies segment, was named group president of Catalent’s newly formed Pharma and Consumer Health segment.
- Jonathan Arnold, who previously served as president of Oral & Specialty Delivery, is Catalent’s new senior VP, chief commercial officer and head of transformation.
- Steven Fasman, who previously served as senior VP and general counsel, will be Catalent’s executive VP and chief administrative officer, a newly created position.
- Karen Flynn has announced her decision to retire from her role as Catalent’s senior VP and chief commercial officer.